Loading...
Understanding the biology of melanoma and therapeutic implications
From 1976 – 2010, the US FDA approved only two medications for the treatment of metastatic melanoma, dacarbazine and high-dose interleukin 2. Between 2011–13, four agents were approved (ipilimumab, vemurafenib, dabrafenib, trametinib) and other therapies have shown great promise in clinical trials....
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2014
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4116747/ https://ncbi.nlm.nih.gov/pubmed/24880940 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.hoc.2014.02.007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|